CETSA MS Profiling for a Comparative Assessment of FDA-Approved Antivirals Repurposed for COVID-19 Therapy Identifies TRIP13 as a Remdesivir Off-Target

by Friman, Tomas, Chernobrovkin, Alexey, Martinez Molina, Daniel, Arnold, Laurence
Published in SLAS Discov (2021)

Positioning High-Throughput CETSA in Early Drug Discovery through Screening against B-Raf and PARP1

by Shaw, Joseph, Dale, Ian, Hemsley, Paul, Leach, Lindsey, Dekki, Nancy, Orme, Jonathan P., Talbot, Verity, Narvaez, Ana J., Bista, Michal, Martinez Molina, Daniel, Dabrowski, Michael, Main, Martin J., Gianni, Davide
Published in SLAS Discov (2018)

Cellular Active N-Hydroxyurea FEN1 Inhibitors Block Substrate Entry to the Active Site

by Exell, Jack C., Thompson, Mark J., Finger, L. David, Shaw, Steven J., Debreczeni, Judit, Ward, Thomas A., McWhirter, Claire, Siöberg, Catrine L. B., Martinez Molina, Daniel, Mark Abbott, W., Jones, Clifford D., Nissink, J. Willem M., Durant, Stephen T., Grasby, Jane A.
Published in Nat Chem Biol (2016)